![[logo] HealthTree Foundation](https://static.healthtree.org/icons/icon_spinner.svg){kind=icon}
![[logo] HealthTree Foundation](https://static.healthtree.org/logo_icon_only.svg){kind=icon}
ASH 2024
1. Updates from ASH-a-Palooza and Mentoring in Hematology/Oncology | Tax Kourelis, MD | #ASH24 Video
1. Balancing Treatment Intervals and Quality of Life in Myeloma | Anna Fleischer | #ASH24 Video
1. IMWG Update: Long-Term Follow-Up, Teclistamab in Relapsed/Refractory #Myeloma | Carlyn Tan, MD | #ASH24 Video
1. Frailty’s Impact on Outcomes in Older MM Patients Treated with Bispecifics | Nadine Abdallah, MD| #ASH24 Video
1. Early Relapse Score in Multiple Myeloma | Meral Beksac, MD | #ASH24 Video
2. Building a Myeloma-Specific Score to Predict CAR-T Therapy Toxicities | Utkarsh Goel MD | #ASH24 Video
3. Gamma Secretase Inhibition May Boost CAR-T Effectiveness in Some Myeloma | Andrew Portugese | #ASH24 Video
4. Update on BMS-986393, a GPRC5D #Myeloma CAR-T | Susan Bal, MD | #ASH24 Video
5. Circulating Tumor Cell As a Biomarker for Outcomes in Myeloma | Luca Bertamini, MD | #ASH24 Video
6. Myeloma Treatment: Teclistamab Outcomes in Academic vs. Community Settings | Adeel Khan, MD | #ASH24 Video
7. Myeloma 11 Trial: Carfilzomib Quadruplet Enhances Overall Survival | Charlotte Pawlyn, MD | #ASH24 Video
8. Daratumumab vs Observation in High-Risk SMM (Aquila Study) | Meletios Dimopoulos, MD | #ASH24 Video
9. ISB 2001 in Relapsed/Refractory #Myeloma: Phase 1 Results | Hang Quach, MD, Cyril Konto, MD | #ASH24 Video
10. ASH 2024 Wrap-Up: What's next in #Myeloma Treatment | Claudio Cerchione, MD | #ASH24 Video
11. Outcomes of Teclistamab in RRMM Patients Who Had Prior BCMA-Directed Therapy | Danai Dima | #ASH24 Video
12. Dara-RVd lite for High Risk Smoldering Myeloma | Omar Nadeem, MD | #ASH24 Video
13. Treating High-Risk Smoldering Myeloma using CAR-T - CAR-PRISM Study | Omar Nadeem, MD | #ASH24 Video
14. Loss of CD38 and Resistance Patterns in Myeloma | Benjamin Diamond, MD | #ASH24 Video
15. Promising Early Data for Improving Talquetamab Effectiveness for MM | Tarek Mouhieddine, MD | #ASH24 Video
16. Real World Experience of Talquetamab in R/R Myeloma Patients | Ariel Grajales Cruz, MD | #ASH24 Video
17. Does enhanced genetic testing impact myeloma patients? | Santiago Thibaud, MD | #ASH24 Video
18. Management and Outcomes of MGRS (Monoclonal Gammopathy of Renal Significance) | Danai Dima | #ASH24 Video
19. High-Fiber NUTRIVENTION Study for Delaying Progression of Myeloma | Urvi Shah, MD | #ASH24 Video
20. Daratumumab for Patient with High-risk Smoldering Myeloma | Rahul Banerjee | #ASH24 Video
21. Understanding the Role of Magnesium for Myeloma Patients | Urvi Shah, MD | #ASH24 Video
22. Daratumumab vs Lenalidomide As Myeloma Maintenance Therapy | Sridevi Rajeeve, MD | #ASH24 Video
23. Daratumumab + Lenalidomide vs Lenalidomide Maintenance in Myeloma | Laahn Foster, MD | #ASH24 Video
24. Plasmacytomas are More Genomically Complex than Myeloma in the Bone Marrow | Urvi Shah, MD | #ASH24 Video
25. Post-CAR-T Driving Restrictions after Week 4 In Myeloma Appear Unnecessary | Rahul Banerjee | #ASH24 Video
26. 24-hour Urine Testing Does Not Add Value to Myeloma Response Assessments | Rahul Banerjee | #ASH24 Video
27. Cevostamab, a FcRH5 bispecific antibody, for RRMM | Joshua Richter, MD | #ASH2024 Video
28. Dara-CyBorD vs CyBorD in Newly Diagnosed AL Amyloidosis| Hans Lee, MD | #ASH2024 Video
29. Social Determinants of Health Impact Myeloma FISH Testing | Amy Pierre, MSN, RN, ANP-BC | #ASH24 Video
30. Belantamab + Standard of Care for Newly Diagnosed Myeloma (DreaMM-9) | Saad Usmani, MD | #ASH24 Video
31. Understanding the ASH Research Collaborative- COSMIC Study | Saad Usmani, MD | #ASH24 Video
32. Teclistamab Step-Up Dosing to Prevent CRS in Relapse/Refractory MM | Jeffrey Matous, MD | #ASH24 Video
33. Beating T-Cell Exhaustion: The Future of Myeloma Care | Marta Chesi , PhD & Erin Meermeier, PhD | #ASH24 Video
34. Ethnicity's Impact on Myeloma Outcomes After Stem Cell Transplant | Frances Cervoni, MD | #ASH24 Video
35. Combination of Isatuximab, Carfilzomib, Lenalidomide, Dex in Myeloma | Elizabeth O'Donnell | #ASH24 Video
36. Boosting Infection Protection in Myeloma Patients with IvIG Therapy | Betsy O’Donnell, MD | #ASH24 Video
37. Inobrodib in Combination with Pomalidomide and Dexamethasone in Myeloma | Emma Searle, MD | #ASH24 Video
38. Adding Isatuximab to Standard RVD May Improve Outcomes for Myeloma Patients | Elias Mai, MD | #ASH24 Video
39. Study Shows Promise for Non-Invasive MRD Testing for Myeloma Patients | Dory Abelman PhD(c) | #ASH24 Video
40. Achieving MRD Negativity: Iberdomide Study for Myeloma Post-AHCT | Natalie Callander, MD | #ASH24 Video
41. Myeloma Updates: High-Risk Smoldering, MRD, IVIG, and Maintenance | Natalie Callander, MD | #ASH24 Video
42. Myeloma Patient Experiences with Talquetamab | Jay Hydren, PhD, CSCS | #ASH24 Video
43. Side Effect Severity & Decision-Making Autonomy in Myeloma | Jay Hydren, PhD, CSCS | #ASH24 Video
44. Myeloma: Real-World Use of Bispecific Antibodies in Community Oncology | Lisa Herms, PhD | #ASH24 Video
45. Improving Myeloma Monitoring: Eliminating Sequential Tests | Jean Sebastien Claveau, MD | #ASH24 Video
46. ICAHT After CAR-T for Myeloma: a Stem Cell Boost Solution | Carolina Schinke, MD | #ASH24 Video
47. Talquetamab Efficacy & Toxicity in African American Myeloma Patients | Carolina Schinke, MD | #ASH24 Video
48. Etentamig with Dexamethasone: Promising 2nd Line Therapy for RRMM | Muhamed Baljevic, MD | #ASH24 Video
49. Combination of Selinexor, Pomalidomide, & Dexamethasone for RRMM | Muhamed Baljevic, MD | #ASH24 Video
50. CAR-T Therapy (ide-cel) Consolidation for Suboptimal ASCT Responders | Barry Paul, MD | #ASH24 Video
51. MRD Status in Myeloma: Insights on Changes During Maintenance | Ross Firestone, MD, PhD | #ASH24 Video
52. KarMMa Study: Immune Profiling in CAR-T Therapy for Myeloma | Bruno Paiva, PhD | #ASH24 Video
53. Impact of Triplet Therapy for Fit Elderly Myeloma Patients | Maria Victoria Mateos, MD, PhD | #ASH24 Video
54. Looking Back: Real-World Data on CAR-T and Bispecifics for RRMM | Natalia Neparidze, MD | #ASH24 Video
55. IVIG and Preventing Infections in Myeloma Patients on Teclistamab | Heloise Cheruvalath | #ASH24 Video
56. CAR-T Efficacy for Myeloma Patients with Bispecific Exposure | Johannes Waldschmidt, MD | #ASH24 Video
57. Anito-Cel, a novel anti-BCMA CAR T-cell, for Relapsed/Refractory Myeloma | Ciara Freeman, MD | #ASH24 Video
58. Anti-BCMA CAR-T Resistance in Myeloma: Genomic Predictors | Francesco Maura, MD | #ASH24 Video
59. Genomic Determinants of Resistance to Anti-BCMA CAR-T Therapies in Myeloma | Ciara Freeman | #ASH24 Video
60. The Unique Power of Whole Genome Sequencing in Multiple Myeloma | Francesco Maura, MD | #ASH24 Video
61. Belentamab Plus Cyclophosphamide & Dexamethasone in RRMM (ProMMise Study) | Rakesh Popat | #ASH24 Video
62. MRD Results from Cartitude-4 (Cilta-Cel vs SOC) in RRMM | Rakesh Popat | #ASH24 Video
63. Phase 1 Study of Antio-cel, an Anti-BCMA CAR-T, for RRMM | Michael Bishop, MD | #ASH24 Video
64. Cytomegalovirus Reactivation in Myeloma Patients on Teclistamab | Francesca Cottini, MD | #ASH24 Video
65. Late Complications and Long-term Care of CAR T-cell Patients | Michael Bishop, MD | #ASH24 Video
66. Real-World Outcomes of Monoclonal Gammopathy of Renal Significance | Francesca Cottini, MD | #ASH24 Video
67. Improving MGUS Care through Collaborative Models and Community-Based Support | Beth Faiman, CNP, PhD | #ASH24 Video
68. Belantamab Mafodotin with Carfilzomib, Lenalidomide, & Dex for Early Relapse Myeloma | Shebli Atrash, MD | #ASH24 Video
69. Optimizing Modakafusp Alfa for Relapsed/Refractory Multiple Myeloma | Shebli Atrash, MD | #ASH24 Video
70. Talquetamab in Myeloma: Results from HealthTree Qualitative Research | Beth Faiman, CNP, PhD | #ASH24 Video
71. KRd vs RD: Reducing Progression in High-Risk Smoldering Myeloma | Annemiek Broijl, PhD | #ASH24 Video
72. New Insights for Amyloidosis in Myeloma | Suzanne Lentzsch, MD | #ASH24 Video
73. Minority Access & Outcomes with Anti-BCMA CAR T Therapy in Myeloma | Luca Paruzzo, MD | #ASH24 Video
74. Demonstrating Better Protection with 3 Flu Shots in Myeloma | Craig Hofmeister, MD, MPH | #ASH24 Video
75. Comparing Outcomes in Younger Multiple Myeloma Patients | Marc Braunstein, MD, PhD | #ASH24 Video
76. Ethnic Disparities in Myeloma Outcomes | Muzaffar Qazilbash, MD | #ASH24 Video
77. DREAMM-7 Trial Update: Belantamab's Impact on Myeloma Treatment | Robert Rifkin, MD | #ASH24 Video
78. MM-6 Trial: In-class transition to Ixazomib in Newly Diagnosed Myeloma | Robert Rifkin, MD | #ASH24 Video
79. Tri-specific Antibody SAR442257 in RRMM and Non-Hodgkin Lymphoma | Fredrik Schjesvold, MD, PhD | #ASH24 Video
80. Teclistamab Optec Trial: Prophylactic Toci and Dex during Step-up Doisng | Robert Rifkin, MD | #ASH24 Video
81. Furthering Our Understanding of Delayed Neurotoxicity Post CAR-T in MM | Anupama Kumar, MD |#ASH24 Video
82. Using whole genome sequencing to differentiate between low-risk and high-risk smoldering myeloma | Mehmet Samur, PhD | #ASH24 Video
83. Improvement of Outcomes in High-risk Myeloma (Optimum/Muknine Trial) | Martin Kaiser | #ASH24 Video
84. Bone Marrow Spatial Signatures Predict Outcomes in R/R Myeloma Patients | Yoshinobu Konishi, MD, PhD | #ASH24 Video
84. Outcomes in Monoclonal Gammopathy of Renal Significance with Novel Agents | Hira Shaikh and Mehndi Dandwani | #ASH24 Video
85. Delayed Neutrophil Recovery Following BCMA-Directed CAR-T in Myeloma | Zachary Avigan, MD | #ASH24 Video
85. Talquetamab in BCMA-Exposed Relapsed/Refractory Multiple Myeloma | Hira Shaikh, MD | #ASH24 Video
86. MRD Progress in Newly Diagnosed #Myeloma, Quad Induction Therapy and ASCT |Luciano Costa, MD| #ASH24 Video
87. Trial of Iberdomide, A Novel CELMoD, In Smoldering Multiple Myeloma | Nisha Joseph, MD | #ASH24 Video
88. Myeloma Patient Preferences: HealthTree Decision-Making Survey | Manni Mohyuddin, MD | #ASH24 Video
89. Can Mass-Fix Replace Bone Marrow Biopsy? | Angela Dispenzieri, MD | #ASH24 Video
90. New Myeloma Combinations Using CELMoD’s and Antibody Drug Conjugates | Paul Richardson, MD | #ASH24 Video
91. Lovesick: Examining Couples Health During Myeloma Transplant | Ashley Rosko, MD | #ASH24 Video
92. MRD2STOP: Can multiple myeloma patients stop treatment? | Ben Derman, MD | #ASH24 Video
Furthering Our Understanding of Delayed Neurotoxicity Post CAR-T in MM | Anupama Kumar, MD |#ASH24
9 months ago
Lesson Description
Join Dr. Anupama Kumar as she shares recent data about delayed neurotoxicity after CAR T-cell therapy with HealthTree University.